Lung Cancer Clinical Trials

⁃ Participants must meet all the following criteria to be eligible for randomization into the study:

• Sign and date the informed consent form prior to the start of any study-specific qualification procedures.

• Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.

• Has histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC).

• The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content.

• Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval of ≥30 days.

• Has at least 1 measurable lesion according to RECIST v1.1 as assessed by the investigator.

• Has documentation of radiological disease progression on or after the most recent systemic therapy.

• Has ECOG PS of ≤1 within 7 days prior to Cycle 1 Day 1 (C1D1).

• Has no evidence of brain or leptomeningeal disease (spinal cord or central nervous system \[CNS\] metastases) based on history and physical examination. Subjects must require no treatment with steroids or anticonvulsants and have a stable neurologic status for at least 2 weeks prior to the first dose of study drug.